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INTRODUCTION
Coronary artery disease is usually caused by atherosclerosis
and associated with traditional risk factors such as smoking,
hypertension, diabetes mellitus, aging, and hyperlipidemia
(1, 2). Besides these traditional risk factors, recently, several
newer risk factors and surrogate markers for the early detec-
tion of atherosclerosis including the measurement of endothe-
lial dysfunction, arterial wall structure, arterial stiffness, and
serologic markers of vascular inflammation were proposed and
widely had been studied (3, 4).
Endothelial dysfunction involves every stages of the pro-
gression of atherosclerosis (5, 6) and is non-invasively mea-
sured by flow-mediated vasodilation (FMD) of the brachial
artery (7). Arterial stiffness is now an established cardiovas-
cular risk factor and one of the best prognostic indicators for
future events in hypertensive population. Pulse wave veloci-
ty (PWV) is a simple, reproducible, and non-invasive mea-
surement which can be used as a valuable index of both arte-
rial stiffness and atherosclerosis in large populations (8). Recent
studies have been demonstrated that high sensitivity C-reac-
tive protein (hsCRP) and microalbuminuria were significant-
ly associated with the presence or severity of atherosclerotic
cardiovascular diseases and could be used as simple surrogates
of atherosclerosis (9-12).
In the previous studies, some kinds of drugs, although they
had individual differences, such as angiotensin converting en-
zyme inhibitor (ACEI), angiotensin receptor blocker, or cal-
cium channel blocker (CCB) could improve endothelial func-
tion and arterial stiffness, and decrease the level of hsCRP and
microalbuminuria (13, 14). However, the effects of CCB mo-
no-therapy and CCB plus ACEI combination therapy on these
surrogate markers in patients with angina pectoris were poor-
ly evaluated.
Therefore, the aim of this study was to evaluate the effects
of CCB and ACEI on surrogate markers of atherosclerosis
including endothelial function, arterial stiffness, urinary albu-
min excretion (UAE), and hsCRP in patients with angina
pectoris.
MATERIALS AND METHODS
Study design
The study is a single-center, randomized, open clinical trial
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Clinical Effects of Calcium Channel Blocker and Angiotensin
Converting Enzyme Inhibitor on Endothelial Function and Arterial
Stiffness in Patients with Angina Pectoris
To evaluate the effects of calcium channel blocker (CCB) and angiotensin convert-
ing enzyme inhibitor (ACEI) on endothelial function and arterial stiffness in stable
angina pectoris (SAP), 87 patients with SAP (57.6±10.0 yr, 52 males) were divid-
ed into two groups; CCB group (group I: n=44, 57.9±9.7 yr, 23 males) vs. CCB plus
ACEI group (group II: n=43, 57.2±10.5 yr, 29 males). Flow mediated vasodilation
(FMD) of the brachial artery, pulse wave velocity (PWV), urinary albumin excretion
(UAE), and high sensitivity C-reactive protein (hsCRP) were compared. FMD, PWV,
UAE, and hsCRP were not different between the groups at baseline. After 6 months
of treatment, FMD were significantly improved in group II (7.5±3.7 to 8.8±2.7%,
p<0.001), but not in group I (7.9±2.7 to 8.2±2.8%, p=0.535). Brachial-ankle PWV
were significantly improved in both groups (1,621.3±279.4 to 1,512.1±225.0 cm/
sec in group I, p<0.001, 1,586.8±278.5 to 1,434.5±200.5 cm/sec in group II, p<
0.001). However, heart-femoral PWV were significantly improved (1,025.7±145.1
to 946.2±112.2 cm/sec, p<0.001) and UAE were significantly decreased (20.19±
29.92 to 13.03±16.42 mg/g Cr, p=0.019) in group II only. In conclusion, combina-
tion therapy with CCB and ACEI improves endothelial function, arterial stiffness,
and UAE than CCB mono-therapy more effectively in patients with SAP.
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ers of atherosclerosis including endothelial function, arterial
stiffness, UAE, and hsCRP in patients with stable angina
pectoris (SAP). The study protocol was approved by the Insti-
tutional Review Board of Chonnam National University Hos-
pital and informed consent was obtained from each patient.
Inclusion criteria were 1) patients with newly diagnosed SAP
who underwent coronary angiography for the first time, 2)
diameter stenosis more than 50% of target lesion, 3) success-
ful, uncomplicated percutaneous coronary intervention with
less than 10% residual stenosis, 4) able to give informed con-
sent, 5) able to successful follow-up measurement of FMD,
PWV, UAE, and hsCRP. Exclusion criteria included 1) prior
history of coronary intervention, 2) blood pressure more than
160 mmHg in systole and 100 mmHg in diastole, 3) known
intolerance to CCB or ACEI, 4) previous use of angiotensin
receptor blocker, 5) known heart failure or ejection fraction
<50%, 6) renal insufficiency with creatinine >2.5 mg/dL,
7) need for warfarin anticoagulation, 8) known hepatic dys-
function, 9) current participation in another randomized
trial, 10) major life threatening illness, 11) patients refusal
during clinical follow-up or incomplete clinical follow-up.
Study subjects
From September 2004 to April 2006, a total of 92 patients
with SAP were enrolled initially. Among them, 5 patients
were excluded owing to the adverse events (intractable cough:
2 patients in group II, headache: 1 patient in group II, facial
flushing: 1 patient in group I, follow-up loss: 1 patient in
group I). Although dry cough was developed in 6 patient of
group II, the symptom was not severe and tolerable in 4 pa-
tients and thus the study was continued except for 2 patients
who complained intractable cough. Therefore, a total of 87
patients (57.6±10.0 yr, 52 males) were finished this study
and analyzed. The patients were divided into two groups ac-
cording to the treatment modalities with 1 to 1 fashion; CCB
(cilnidipine 10 mg per day) group (group I: n=44, 57.9±
9.7 yr, 23 males) and CCB (cilnidipine 10 mg per day) plus
ACEI (captopril 25 mg per day) group (group II: n=43, 57.2
±10.5 yr, 29 males). FMD, PWV, UAE, and hsCRP were
compared at baseline and 6 months after treatment. All param-
eters were measured early in the morning following overnight
fasting more than 12 hr. Vasoactive medications including
long-acting nitrates or intravenous nitrates or CCB or ACEI
were withheld and not prescribed for at least 24 hr until the
baseline measurements were completed. Only short-acting
sublingual nitroglycerin for control of angina and anti-platelet
agents were permitted. The doses of CCB or ACEI were not
changed during the study periods. Follow-up measurements
were also preformed early in the morning after 6 months of
medical treatment at more than 12 hr after last dosing.
Measurement of endothelial function
FMD of the brachial artery as the non-invasive parameter
of endothelial function was measured according to the guide-
line described previously (7). A 8 MHz high resolution linear
vascular ultrasound transducer was used to image the brachial
artery longitudinally just above the antecubital fossa. The to-
urniquet measuring blood pressure was placed on the forearm
in order to create shear stress induced by reactive hyperemia.
The diameter of the brachial artery was measured at the onset
of the R-wave on electrocardiogram. After baseline measure-
ments of the brachial artery diameter, the blood pressure cuff
was inflated to at least 50 mmHg above systolic blood pres-
sure to occlude arterial flow for 5 min. Subsequent deflation
of the cuff induces a brief high flow state through the brachial
artery (reactive hyperemia) to accommodate the dilated resis-
tance vessels. The resulting increase in shear stress causes the
brachial artery to dilate. The brachial artery was imaged for
the first 2 min of reactive hyperemia continuously. The flow-
mediated dilatory response was used as a measure of endothe-
lium dependent vasodilation. After the 10 min of rest to re-
establish baseline condition, 0.6 mg of nitroglycerin was ad-
ministered sublingually. The brachial artery was imaged for
5 min continuously to measure peak diameter. The dilatory
response to nitroglycerin was used as a measure of endothe-
lium independent vasodilation.
Measurement of arterial stiffness
Assessment of arterial stiffness was performed non-invasive-
ly with the commercially available VP-2000 PWV analysis
system (Colins, Komaki, Japan). All PWV measurements
were performed by the single well-trained clinical technician
at supine position in a quiet, temperature controlled room
after at least 10 min of rest. Heart-femoral and brachial-ankle
PWV were measured and used for analysis. Brachial-ankle
PWV were calculated from the mean value of the right and
left brachial- ankle PWV.
Measurements of UAE and hsCRP
UAE was measured by turbidimetric immunoassay method
using Olympus 5431 autoanalyzer in a spot urine samples
by simultaneously assessing creatinine excretion (mg/g Cr),
collected from the first voided mid-stream urine. The level
of hsCRP was measured by immunoturbidimetric CRP-Latex
(II) assay using Olympus 5431 autoanalyzer. The sample for
the measurement of hsCRP was obtained early morning in
overnight fasting more than 12 hr before coronary angiog-
raphy or intervention.
Study endpoints
Primary endpoints were changes of FMD, PWV, UAE, and
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cardiac events including death, myocardial infarction, and tar-
get lesion revascularization during the study periods between
the groups.
Statistical analysis
Statistical analysis was performed using commercially avail-
able software (SPSS for Windows, Version 13.0, Chicago, IL,
U.S.A.). All parameters were expressed as the mean±stan-
dard deviation. Categorical variables were evaluated using chi-
square test. Differences in the mean values between the 2 gro-
ups were evaluated using unpaired t-test and changes in the
mean values using paired t-test. Numerical correlations were
established by a Spearman correlation. A p value of less than
0.05 was considered to be statistically significant.
RESULTS
Baseline clinical characteristics
The study population consisted of 87 patients (57.6±
10.0 yr, 52 males) with stable angina pectoris who had
newly diagnosed coronary artery disease by coronary angiog-
raphy. Baseline clinical characteristics including age, sex,
risk factors, and prescribed medications were not different
between the groups (Table 1).
Angiographic characteristics
Angiographic characteristics are summarized in Table 2.
Baseline angiographic variables including target lesion, num-
ber of diseased vessel, types of implanted stent, lesion mor-
phology, and severity of diameter stenosis were not different
between the groups.
Baseline measurements of FMD, PWV, UAE, and hsCRP
FMD of the brachial artery was 7.7±3.2% and nitroglyc-
erin mediated vasodilation was 16.8±4.6%. Heart-femoral
PWV was 1,020.3±146.1 cm/sec and brachial-ankle PWV
was 1,604.3±277.9 cm/sec (right: 1,598.7±276.1, left:
1,609.7±285.6). UAE was 17.1±24.7 mg/g Cr and the
level of hsCRP was 0.23±0.37 mg/dL. Heart-femoral PWV
were significantly correlated with brachial-ankle PWV (r=
0.73, p<0.01) (Fig. 1). UAE were significantly correlated with
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LDL, low-density lipoprotein; HDL, high-density lipoprotein; LVEF, left ven-
tricular ejection fraction.
Group I (n=44) Group II (n=43) p value
Age (yr) 57.9±9.7 57.2±10.5 0.731
Males (%) 23 (52.3) 29 (64.1%) 0.149
Height (cm) 164.1±8.2 166.2±6.5 0.182
Weight (kg) 69.2±10.6 70.1±9.0 0.763
Smoking (%) 20 (45.5) 22 (51.2) 0.594
Hypertension (%) 20 (45.5) 17 (39.5) 0.577
Diabetes mellitus (%) 12 (27.3) 13 (29.6) 0.760
Total cholesterol (mg/dL) 194.7±44.7 192.4±33.3 0.783
LDL cholesterol (mg/dL) 136.8±41.4 134.9±31.4 0.816
HDL cholesterol (mg/dL) 49.7±11.5 46.8±9.8 0.202
Triglyceride (mg/dL) 114.5±43.6 122.7±58.4 0.458
Prescribed medications (%)
Aspirin 44 (100.0) 43 (100.0) 1.000
Clopidogrel 39 (88.6) 40 (93.0) 0.479
Nitrates 33 (76.7) 29 (67.4) 0.436
Statins 25 (56.8) 23 (53.5) 0.755
Beta-blockers 15 (34.1) 12 (27.9) 0.533
LVEF (%) 67.9±7.7 69.7±6.5 0.319
Table 1. Baseline clinical characteristics between the groups
ACC/AHA, American College of Cardiology/American Heart Association;
TIMI, thrombolysis in myocardial infarction.
Group I Group II
p value
(n=44) (n=43)
Target lesion (%) 0.721
Left anterior descending artery 23 (52.3) 19 (44.2)
Right coronary artery 14 (31.8) 15 (34.9)
Left circumflex artery 7 (15.9) 9 (20.9)
Number of involved vessel (%) 0.624
Single vessel disease 23 (52.3) 24 (55.8)
Two vessel disease 17 (38.6) 13 (30.2)
Three vessel disease 4 (9.1) 6 (14.0)
Types of stent (%) 0.670
Drug eluting stent 41 (93.2) 39 (90.7)
Bare metal stent 3 (6.8) 4 (9.3)
ACC/AHA lesion morphology (%) 0.456
Simple lesion (A/B1) 25 (56.8) 21 (48.8)
Complex lesion (B2/C) 19 (43.2) 22 (51.2)
TIMI flow (%) 0.730
O 0 (0) 0 (0)
I 0 (0) 0 (0)
II 6 (13.6) 7 (16.3)
III 38 (86.4) 36 (83.7)
Diameter stenosis (%) 89.1±8.6 90.5±10.2 0.276
Table 2. Angiographic characteristics between the groups
Fig. 1. Relation between heart-femoral pulse wave velocity (PWV)
and brachial-ankle PWV.
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r=0.73
p<0.01heart-femoral PWV (r=0.51, p<0.01) and brachial-ankle PWV
(r=0.43, p<0.01) (Fig. 2). However, FMD and hsCRP were not
correlated with PWV or UAE. FMD, PWV, UAE, and hsCRP
were not different between the groups at baseline (Table 3).
Changes of FMD, PWV, UAE, hsCRP, and hemodynamic
parameters
FMD, PWV, UAE, and hsCRP were measured in all pati-
ents after 6 months of medical treatment. FMD were signif-
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Fig. 2. Relation between urinary albumin excretion (UAE) and pulse wave velocity (PWV).
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FMD, flow-mediated vasodilation; NMD, nitroglycerin-mediated vasodilation; hfPWV, heart-femoral pulse wave velocity; baPWV, brachial-ankle pulse
wave velocity; UAE, urinary albumin excretion; hsCRP, highly sensitive C-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure;
HR, heart rate.
Group I (n=44) Group II (n=43)
Baseline Follow-up p value Baseline Follow-up p value
FMD (%) 7.9±2.7 8.2±2.8 0.535 7.5±3.7 8.8±2.7 <0.001
NMD (%) 17.5±8.6 18.3±9.1 0.082 16.1±10.2 16.4±9.7 0.682
HfPWV (cm/sec) 1,015.1±148.6 1,000.1±132.8 0.060 1,025.7±145.1 946.2±112.2 <0.001
BaPWV (cm/sec) 1,621.3±279.4 1,512.1±225.0 <0.001 1,586.8±278.5 1,434.5±200.5 <0.001
UAE (mg/g Cr) 14.15±18.19 12.80±15.50 0.214 20.19±29.92 13.03±16.42 0.019
HsCRP (mg/dL) 0.19±0.33 0.16±0.20 0.307 0.25±0.42 0.21±0.25 0.111
SBP (mmHg) 136.4±11.2 131.5±9.1 <0.001 135.7±12.2 127.8±9.4 <0.001
DBP (mmHg) 82.2±7.4 79.6±6.7 0.001 83.6±7.8 79.7±6.4 <0.001
HR (rate/min) 65.0±8.2 65.2±7.8 0.547 65.2±9.2 64.8±8.0 0.446
Table 3. FMD, PWV, UAE, hsCRP, and hemodynamic parameters at baseline and at 6 months
Fig. 3. Changes of flow-mediated vasodilation (FMD) of the brachial artery after 6 months of medical therapy.
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Baseline Follow-upicantly improved in group II (7.5±3.7 to 8.8±2.7%, p<
0.001), but not in group I (7.9±2.7 to 8.2±2.8%, p=0.535)
(Fig. 3). FMD was improved in 31 patients and not changed
or decreased in 12 patients of group II. PWV were more de-
creased in patients with the improvement of FMD than in
patients without improvement of FMD, but it did not reached
statistical significance (hfPWV: -93.6±148.6 vs. -58.9±
75.7 cm/sec, baPWV: -127.3±193.7 vs. -75.1±110.4 cm/
sec, p=ns). Brachial-ankle PWV were significantly improved
in both groups (1,621.3±279.4 to 1,512.1±225.0 cm/sec
in group I, p<0.001, 1,586.8±278.5 to 1,434.5±200.5
cm/sec in group II, p<0.001) (Fig. 4). However, heart-femoral
PWV were significantly improved only in group II (1,025.7
±145.1 to 946.2±112.2 cm/sec, p<0.001), but not in group
I (1,015.1±148.6 to 1,000.1±132.8 cm/sec, p=0.06) (Fig.
5). FMD was improved in 31 patients and not changed or
decreased in 12 patients of group II. The improvement of
FMD was not associated with the changes of PWV. UAE were
significantly decreased only in group II (20.19±29.92 to
13.03±16.42 mg/g Cr, p=0.019), but not in group I (14.15
±18.19 to 12.80±15.50 mg/g Cr, p=0.214). The levels of
hsCRP were not changed in both groups (0.19±0.33 to 0.16
±0.20 mg/dL in group I, p=0.307, 0.25±0.42 to 0.21±
0.25 mg/dL in group II, p=0.111). Systolic and diastolic blood
pressures were significantly improved in both groups, but
were not different between the groups at 6 months. Heart
rates were not changed in both groups and were not differ-
ent between the groups at 6 months. Changes of FMD, PWV,
UAE, hsCRP, and hemodynamic parameters were summa-
rized in Table 3. FMD was improved in 31 patients and not
changed or decreased in 12 patients of group II. The improve-
ment of FMD was not associated with the changes of PWV.
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Fig. 5. Changes of brachial-ankle pulse wave velocity (PWV) after 6 months of medical therapy.
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Fig. 4. Changes of heart-femoral pulse wave velocity (PWV) after 6 months of medical therapy.
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Baseline Follow-upClinical events during follow-up periods
Clinical follow-up were possible in all patients. Death, my-
ocardial infarction, or stent thrombosis was not developed in
both groups. Follow-up coronary angiography at 6 months was
performed in 55 patients (29 patients in group I, 26 patients
in group II). Target lesion revascularization were performed
in 5 patients (9.1%) due to restenosis and were not different
between the groups (3 patients: 10.4% in group I, 2 patient:
7.7% in group II, p=0.763). Baseline and follow-up values
of FMD, PWV, UAE, and hsCRP were not associated with
angiographic restenosis.
DISCUSSIONS
The main finding of the present study is that the combi-
nation therapy with CCB and ACEI more effectively improves
endothelial function, arterial stiffness, and UAE than CCB
mono-therapy do in patients with stable angina pectoris. Am-
erican College of Cardiology/American Heart Association
2002 update guideline for the management of stable angina
recommended that ACEI should be used in most cases as a
routine secondary prevention for patients with known coro-
nary artery disease based on the results of the Heart Outcomes
Prevention Evaluation trial (15). However, the precise bene-
ficial mechanism of ACEI in angina pectoris was not eluci-
dated. Several mechanisms such as anti-proliferative effects,
hormonal/vascular effects and anti-atherogenic properties were
suggested as a favorable role of ACEI. Although the major
adverse cardiac events were not different between the groups,
the results of this study also support that ACE inhibition plays
a beneficial role in the management of stable angina pectoris
by anti-atherogenic effects including improvements of endo-
thelial dysfunction, arterial stiffness, and UAE.
Recently, several surrogate markers for the early detection
of atherosclerosis including the measurement of endothelial
dysfunction, arterial wall structure, arterial stiffness, and sero-
logic markers of vascular inflammation were proposed and
widely studied (3, 4). Recent studies suggested that these sur-
rogate markers for atherosclerosis are associated with the pres-
ence of atherosclerotic coronary artery disease and also asso-
ciated with future adverse cardiac events (8-12). To reduce
the risk of death or disability associated with atherosclerotic
coronary artery disease, therefore, early identification and ther-
apeutic modification of risk factors or surrogate markers are
important.
Endothelial dysfunction measured by FMD of the brachial
artery is associated with the presence of coronary artery dis-
ease or the severity of the coronary artery stenosis or in-stent
restenosis following percutaneous coronary intervention (16,
17). Some kinds of drugs such as ACEI, angiotensin recep-
tor blocker, or CCB are known to have beneficial effects on
endothelial function in the previous studies. Mancini et al.
(18) reported that ACEI (quinapril) could improve endothe-
lial function measured by invasive measurements of coronary
diameter change in response to acetylcholine in patients with
coronary artery disease. Anderson et al. (19) also reported that
ACEI (quinapril) could improve endothelial function mea-
sured by FMD of the brachial artery in patients with coronary
artery disease, but CCB (amlodipine) could not improve FMD.
In this study, combination therapy with ACEI (captopril) and
CCB (cilnidipine) showed significant improvement in endo-
thelial function measured by FMD of the brachial artery in
patients with coronary artery disease. However, CCB mono-
therapy did not improve FMD of the brachial artery. The re-
sults of this study and Anderson et al. (19) suggested that
ACE inhibition may play more important roles in endothe-
lial function than calcium channel blockade in patients with
overt coronary artery disease. Although FMD of the brachial
artery were improved only in combination therapy group,
clinical events were not different between the groups. FMD
of the brachial artery were not associated with in-stent resteno-
sis in this study. However, Kitta et al. (16) and Patti et al. (17)
reported that impaired FMD of the brachial artery was a sig-
nificant independent predictor of late in-stent restenosis fol-
lowing percutaneous coronary intervention. To date, no pros-
pective randomized clinical trial in large population has eval-
uated the relationship between endothelial dysfunction and
in-stent restenosis. Thus, further clinical trials will be need-
ed to elucidate the relationship between endothelial dysfunc-
tion and in-stent restenosis.
Arterial stiffness is now an established risk factor for pre-
mature coronary artery disease, peripheral vascular disease, and
stroke (8). It is a single best prognostic indicator for future
cardiovascular events in hypertensive population and also pre-
dicts adverse outcomes in patients with documented coronary
artery disease (20-24). PWV is a simple, reproducible, and
non-invasive measurement which can be used as a valuable
index of both arterial stiffness and atherosclerosis in large pop-
ulations. The results of the studies including Nigam et al. (25,
26) suggested that large conduit artery stiffness correlates sig-
nificantly with FMD of the brachial artery. However, the re-
sults of this study failed to demonstrate the relationship be-
tween PWV and FMD of the brachial artery at baseline and
after 6 months of medical treatment. Although the PWV was
more decreased in patients who showed the improvement of
FMD, it did not reached statistical significance. Life style mod-
ifications and pharmacological therapy could improve arteri-
al stiffness measured by PWV. Long-term ACEI therapy has
been shown to be superior to diuretics or beta-blockers in im-
proving carotid, femoral, or radial arterial compliance and is
marginally superior to CCB therapy as well (14). CCB as a
mono-therapy or combination therapy with ACEI improved
brachial-ankle PWV, but heart-femoral PWV was only im-
proved in combination therapy with ACEI and CCB in the
present study. This finding suggested that combination ther-
apy with ACEI and CCB could have more favorable effects on
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reason why heart-femoral PWV and brachial-ankle PWV
showed different response is not clear, but several possible
mechanisms would have been involved. Firstly, the improve-
ment of heart-femoral PWV in group II is possibly associat-
ed with the pleiotropic effect of ACEI such as the favorable
impacts on the aortic wall endothelial function or components.
ACEI is known to be decrease collagen content, fibrosis, and
thus improve elasticity. Secondly, the improvement of heart-
femoral PWV in group II is possibly caused by the simple
hemodynamic change of BP. Although the change of BP did
not showed significant statistical difference, the drop of BP
in group II was about 3 mmHg more than in group I. Fur-
thermore, ACEI showed different response on central aortic
pressure according to the age group in the previous studies.
According to the study of Morgan et al. (27), ACEI therapy,
despite a relatively small effect on peripheral BP, showed a
more beneficial effect on central BP in elderly patients with
hypertension. We did not checked central aortic pressure in
the present study, but the changes of central aortic pressure
in group II might be significantly higher than the changes
of peripheral brachial BP. Thirdly, the number of the subjects
involved in this study is relatively small and thus it also may
affect the result of the heart-femoral PWV.
HsCRP is an important surrogate marker for atherosclerot-
ic coronary artery disease and associated with cardiovascular
events in patients with documented coronary artery disease
(9, 10). We want to evaluate the relationship between hsCRP
and other surrogate markers for atherosclerosis, and also the
effects of pharmacologic treatment with CCB or CCB plus
ACEI on the level of hsCRP. Several studies demonstrated
that the level of hsCRP were significantly associated with
FMD of the brachial artery, PWV, and UAE and improved
by pharmacological therapy (28-31). However, the level of
hsCRP were not correlated with FMD of the brachial artery
or PWV, or UAE and not changed with pharmacologic treat-
ments in this study. The correlation among these surrogate
markers has not been reported consistently in the previous
studies (26, 32, 33). None of the surrogate markers provides
highly sensitive and specific recognition of progressive athe-
rosclerotic cardiovascular diseases and rather than these sur-
rogate markers may have different supplemental action mech-
anism in the development of atherosclerotic coronary artery
disease (33). Therefore, an attractive strategy has been to use
a combination of these surrogates to better define the pres-
ence of early disease.
Microalbuminuria measured by UAE is also an important
surrogate marker for atherosclerosis and predicts future car-
diac events (11, 12). UAE was significantly improved after
combination therapy with CCB and ACEI, but not after CCB
mono-therapy in the present study. This finding support that
the inhibition of renin-angiotensin-aldosterone system can
retard or reverse microalbuminuria (34). Although the change
of UAE was not compared between the groups, however, the
baseline level of UAE was significantly lower in group I than
in group II. Therefore, we cannot exclude that the lower ch-
anges of UAE in group I might be caused by the lower base-
line level than in group II. Recently, Morimoto et al. (35) re-
ported that CCB (cilnidipine) was associated with the impro-
vement in UAE besides the improvement of brachial-ankle
PWV. This study showed the same finding compared with
the present study in that CCB could improve brachial-ankle
PWV, but the effect of CCB on UAE was the opposite. Their
study also had a limitation that only the small numbers of
the study population was involved. Therefore, the effect of
cilnidipine on UAE should be considerably re-evaluated by
more large randomized controlled trial.
There are some limitations in this study. Firstly, the main
limitation of this study was the relatively small sample size
and thus some selection bias could present inevitably. Second-
ly, although the prescribed medications such as statins or beta-
blockers were not different between the groups, these drugs
also could affect diversely on FMD, PWV, and UAE. Third-
ly, although the degree of the fall of BP did not showed sig-
nificant statistical difference between the groups, the greater
fall of BP in group II than in group I would have affect the
greater improvement of endothelial function and arterial stiff-
ness in group II than in group I. Therefore, the degree of BP
change between the groups should be controlled at a similar
degree in the study design by adding hydrochlothiazide as a
placebo in group I. Fourthly, the dose of the used ACEI was
fixed (25 mg per day) and thus not reached its full dose. It may
not be sufficient to evaluate the effect of ACEI.
In conclusion, combination therapy with CCB and ACEI
more effectively improve endothelial dysfunction, arterial stiff-
ness, and microalbuminuria than CCB mono-therapy in pa-
tients with angina pectoris.
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